VIVO - Meridian Bioscience, Inc.
| Previous Close | 6.97 |
| Open | 6.77 |
| Bid | 6.01 x 900 |
| Ask | 8.00 x 800 |
| Day's Range | 6.57 - 7.20 |
| 52 Week Range | 5.51 - 17.71 |
| Volume | 563,692 |
| Avg. Volume | 690,066 |
| Market Cap | 301.091M |
| Beta (5Y Monthly) | 0.50 |
| PE Ratio (TTM) | 15.69 |
| EPS (TTM) | 0.45 |
| Earnings Date | Feb 06, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Jan 31, 2019 |
| 1y Target Est | 9.00 |
- GlobeNewswire
Meridian Bioscience Supports Diagnostic Companies in Fighting Coronavirus Pandemic by Providing Zero Cost Proprietary Technology for Evaluation
In order to help expedite such development, Meridian is pleased to provide from stock its specialized enzyme formulations to manufacturers of a COVID-19 molecular detection assay at no cost for the purpose of initial testing and evaluation. Following the successful development of a COVID-19 detection assay or kit, it is Meridian’s commitment to continue to manufacture and supply its propriety formulations at commercial scale in order to meet the global demand.
- GlobeNewswire
Meridian Bioscience Announces FDA-Clearance for New Curian™ Analyzer and the Curian™ HpSA® Assay
CINCINNATI, March 16, 2020 -- Meridian Bioscience, Inc. (NASDAQ: VIVO) a provider of immunoassay, molecular, and blood chemistry diagnostic testing solutions, today announced.
- Simply Wall St.
Trade Alert: The President Of Meridian Bioscience, Inc. (NASDAQ:VIVO), John Kenny, Has Just Spent US$174k Buying Shares
Investors who take an interest in Meridian Bioscience, Inc. (NASDAQ:VIVO) should definitely note that the President...
- Simply Wall St.
How Does Meridian Bioscience's (NASDAQ:VIVO) P/E Compare To Its Industry, After The Share Price Drop?
To the annoyance of some shareholders, Meridian Bioscience (NASDAQ:VIVO) shares are down a considerable 33% in the...
- American City Business Journals
Here's how Cincinnati stocks did on Dow's 1,200-point surge
The U.S. stock market rallied on Wednesday, with the Dow Jones industrial average shooting up nearly 1,200 points following a Super Tuesday surge for Democratic presidential candidate Joe Biden. Shares in Cincinnati-based companies rode that wave.
- GlobeNewswire
Meridian’s Novel Air-Dryable qPCR Mix Decreases Costs and Simplifies Workflows for Molecular Test Manufacturers
CINCINNATI, Feb. 26, 2020 -- Meridian Bioscience, Inc. (NASDAQ: VIVO), following the extremely successful launch of the Lyo-Ready qPCR mixes, is proud to introduce today its.
- American City Business Journals
UPDATE: These Cincinnati stocks took biggest hits in Monday's selloff
Greater Cincinnati stocks took a beating on Monday as the stock market plummeted in the wake of an escalation in coronavirus cases.
- Simply Wall St.
Meridian Bioscience, Inc. (NASDAQ:VIVO) Earns Among The Best Returns In Its Industry
Today we'll evaluate Meridian Bioscience, Inc. (NASDAQ:VIVO) to determine whether it could have potential as an...
- American City Business Journals
One of Cincinnati’s largest public companies to acquire rival for $49M
Meridian Bioscience Inc. disclosed Feb. 19 that the Newtown-based maker of diagnostic test kits plans to acquire another public company, Exalenz Bioscience Ltd. of Israel, for about $49 million in cash. Meridian (Nasdaq: VIVO) cited a desire to add Exalenz’s flagship BreathID Breath Test Systems platform for the detection of Helicobacter pylori, a bacteria often associated with peptic ulcers and gastric cancer. Meridian will discuss the financial impact of the transaction during its fiscal second quarter earnings call in May. The Israeli company’s shares are traded on the Tel Aviv Stock Exchange, and the acquisition is subject to Exalenz shareholder approval.
- GlobeNewswire
Meridian Bioscience Signs Definitive Agreement to Acquire Exalenz Bioscience; Adds State-Of-The-Art Urea Breath Test Diagnostics Platform
Meridian Bioscience, Inc. (VIVO) and Exalenz Bioscience Ltd. (TASE:EXEN) announced today that the two companies have entered into a definitive agreement for Meridian to acquire Exalenz for ₪6.10 per share in cash with an implied transaction value of approximately $49 million. With this acquisition, Meridian will be adding Exalenz’s flagship BreathID® Breath Test Systems, a urea breath test platform for the detection of Helicobacter pylori, often associated with peptic ulcers and gastric cancer.
- Thomson Reuters StreetEvents
Edited Transcript of VIVO earnings conference call or presentation 7-Feb-20 3:00pm GMT
Q1 2020 Meridian Bioscience Inc Earnings Call
- Zacks
Meridian Bioscience (VIVO) Beats Q1 Earnings Estimates
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 66.67% and -2.64%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Meridian Bioscience Reports First Quarter Fiscal 2020 Operating Results and Reaffirms 2020 Guidance
CINCINNATI, Feb. 07, 2020 -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2019. First Quarter Fiscal.
- Zacks
Analysts Estimate Meridian Bioscience (VIVO) to Report a Decline in Earnings: What to Look Out for
Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- MarketWatch
Coronavirus update: Vaccine stocks retreat and airport screening expands to 20 U.S. airports
A nearly weeklong rally for vaccine and diagnostics developers looking to capitalize on the coronavirus outbreak ended on Tuesday.
- American City Business Journals
Stock soars for Cincinnati firm that could help combat coronavirus
Over the last few days, the company has seen significant demand for one of its products, which enables laboratories in China to develop fast and accurate screening assays for the deadly new strain of virus.
- GlobeNewswire
Meridian Bioscience Lyo-Ready 1-Step RT-qPCR Mix is Used in the Development of Molecular Diagnostics for New Coronavirus Outbreak
Meridian Bioscience, Inc. (VIVO) today announced a novel coronavirus, identified by Chinese authorities on January 7 and currently named 2019-nCoV, is a new strain that had not been previously identified in humans. This new virus has already spread to other parts of mainland China and several other countries and health authorities around the world are taking action to prevent a global epidemic. The World Health Organization (WHO) has provided interim guidance to laboratories and stakeholders involved in laboratory testing of patients who meet the definition of suspected case of pneumonia associated with 2019-nCoV.
- GlobeNewswire
Meridian Launched a New High-Fidelity Polymerase to Offer Robust Amplification for NGS and PCR Applications
CINCINNATI, Jan. 23, 2020 -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced the launch of a High-Specificity Pfu HS Mix that not only provides high-fidelity.
- Simply Wall St.
Do You Like Meridian Bioscience, Inc. (NASDAQ:VIVO) At This P/E Ratio?
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios...
- GlobeNewswire
Meridian Bioscience to Hold First Quarter 2020 Financial Results Conference Call on February 7, 2020
CINCINNATI, Jan. 15, 2020 -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report first quarter 2020.
- GuruFocus.com
A Duo of Underperforming Stocks to Ease
Sell-side anaysts also recommend selling shares of these companies Continue reading...
- Simply Wall St.
Is There An Opportunity With Meridian Bioscience, Inc.'s (NASDAQ:VIVO) 22% Undervaluation?
In this article we are going to estimate the intrinsic value of Meridian Bioscience, Inc. (NASDAQ:VIVO) by taking the...
- Insider Monkey
Meridian Bioscience, Inc. (VIVO): Are Hedge Funds Right About This Stock?
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
- American City Business Journals
Multimillion-dollar settlement proposed in lawsuit over stock price at one of region’s largest public companies
A hearing has been scheduled in federal court in Cincinnati so a judge can determine whether to approve a proposed $2.1 million settlement in a class-action lawsuit filed against Meridian Bioscience following dips in the firm’s stock price in 2017.
- Thomson Reuters StreetEvents
Edited Transcript of VIVO earnings conference call or presentation 7-Nov-19 3:00pm GMT
Q4 2019 Meridian Bioscience Inc Earnings Call
